These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21395648)

  • 1. Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam.
    Bae JW; Choi CI; Jang CG; Lee SY
    Br J Clin Pharmacol; 2011 Apr; 71(4):550-5. PubMed ID: 21395648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.
    Lee HI; Bae JW; Choi CI; Lee YJ; Byeon JY; Jang CG; Lee SY
    Pharmacogenet Genomics; 2014 Feb; 24(2):113-7. PubMed ID: 24322170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population.
    Zhang M; Yang Y; Zhao G; Di X; Xu L; Jiang N; Xu J; Xu X
    Genet Mol Res; 2014 Feb; 13(1):831-7. PubMed ID: 24615047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.
    Choi CI; Kim MJ; Jang CG; Park YS; Bae JW; Lee SY
    Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):476-80. PubMed ID: 21726410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of meloxicam in healthy Chinese volunteers].
    Xu HY; Zhong DF; Zhao LM; Zhang YF; Zhang BJ
    Yao Xue Xue Bao; 2001 Jan; 36(1):71-3. PubMed ID: 12579866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to Suarez-Kurtz's comments on strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.
    Lee HI; Bae JW; Choi CI; Lee YJ; Byeon JY; Jang CG; Lee SY
    Pharmacogenet Genomics; 2014 Aug; 24(8):407-8. PubMed ID: 25003538
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of oxicam NSAIDs.
    Suarez-Kurtz G
    Pharmacogenet Genomics; 2014 Aug; 24(8):406-7. PubMed ID: 25003537
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.
    Kirchheiner J; Meineke I; Steinbach N; Meisel C; Roots I; Brockmöller J
    Br J Clin Pharmacol; 2003 Jan; 55(1):51-61. PubMed ID: 12534640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects.
    Bae JW; Kim JH; Choi CI; Kim MJ; Kim HJ; Byun SA; Chang YS; Jang CG; Park YS; Lee SY
    Arch Pharm Res; 2009 Feb; 32(2):269-73. PubMed ID: 19280158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs].
    Poulsen Nautrup B; Hörstermann D
    Dtsch Tierarztl Wochenschr; 1999 Mar; 106(3):94-100. PubMed ID: 10220944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.
    López-Rodríguez R; Novalbos J; Gallego-Sandín S; Román-Martínez M; Torrado J; Gisbert JP; Abad-Santos F
    Pharmacol Res; 2008 Jul; 58(1):77-84. PubMed ID: 18694831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug.
    Davies NM; Skjodt NM
    Clin Pharmacokinet; 1999 Feb; 36(2):115-26. PubMed ID: 10092958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.
    Bae JW; Choi CI; Lee HI; Lee YJ; Jang CG; Lee SY
    Int J Clin Pharmacol Ther; 2012 Sep; 50(9):683-9. PubMed ID: 22735459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers.
    Shao H; Ren XM; Liu NF; Chen GM; Li WL; Zhai ZH; Wang DW
    J Clin Pharm Ther; 2010 Jun; 35(3):351-60. PubMed ID: 20831536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects].
    Zhang YF; Chen XY; Guo YJ; Si DY; Zhou H; Zhong DF
    Yao Xue Xue Bao; 2005 Sep; 40(9):796-9. PubMed ID: 16342679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of single and multiple oral doses of meloxicam in adult horses.
    Noble G; Edwards S; Lievaart J; Pippia J; Boston R; Raidal SL
    J Vet Intern Med; 2012; 26(5):1192-201. PubMed ID: 22860573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.
    Hasunuma T; Tohkin M; Kaniwa N; Jang IJ; Yimin C; Kaneko M; Saito Y; Takeuchi M; Watanabe H; Yamazoe Y; Uyama Y; Kawai S
    Br J Clin Pharmacol; 2016 Jun; 81(6):1078-90. PubMed ID: 26774055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of meloxicam in piglets.
    Fosse TK; Haga HA; Hormazabal V; Haugejorden G; Horsberg TE; Ranheim B
    J Vet Pharmacol Ther; 2008 Jun; 31(3):246-52. PubMed ID: 18471146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?
    Rodrigues AD
    Drug Metab Dispos; 2005 Nov; 33(11):1567-75. PubMed ID: 16118328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
    Yin OQ; Tomlinson B; Chow MS
    Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.